TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03118570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: tablets
Study: NCT01056614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study: NCT03706690

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
Study: NCT01390818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B (pimasertib)
Description: MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
Study: NCT01056614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04937192

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03130569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Module Group
Study: NCT00827957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Cooling
Description: The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Cooling
Description: The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
Study: NCT03118570

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid (optional)
Description: Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid (optional)
Description: Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid (optional)
Description: Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid (optional)
Description: Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
Study: NCT03544879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Education
Description: The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works \& What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
Study: NCT02459145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graduated exercise protocol
Description: Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
Study: NCT02930616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patients in Group 2 will receive WLE at first and pCLE 2 months later.
Study: NCT02459145

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Graduated exercise protocol
Description: Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
Study: NCT01240512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
Study: NCT04799951

Intervention type: OTHER
Intervention: a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.
Description: an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
Study: NCT02623595

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: A type of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: Immune modulating agents
Study: NCT04637971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help tips plus telephone support
Description: Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
Study: NCT03045471

Intervention type: DRUG
Intervention: R-EPOCH
Description: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.

Intervention type: DRUG
Intervention: R-CHOP
Description: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
Study: NCT01390818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409 (PI3K and mTOR inhibitor)
Description: SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B (pimasertib)
Description: MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
Study: NCT01954251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
Study: NCT02350933

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy
Description: A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
Study: NCT00818285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDS for psychotropic drug management
Description: Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
Study: NCT00868166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime
Description: 2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole given as add-on therapy 50mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Riluzole given as add-on therapy 50mg bid
Study: NCT01507844

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: positive ventilation
Description: 10 minutes of increased 4,7,12 positive pressure ventilation
Study: NCT02098460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin, Probucol, Cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin, Probucol, Cilostazol
Study: NCT02441855

Intervention type: DEVICE
Intervention: echocardiography
Description: echocardiography: Left and right ventricular functions and aortic elastic properties.

Intervention type: DEVICE
Intervention: echocardiography
Description: echocardiography: Left and right ventricular functions and aortic elastic properties.
Study: NCT00643604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil sodium
Description: rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
Study: NCT03335787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
Study: NCT02252237

Intervention type: BIOLOGICAL
Intervention: Pharmacokinetic
Description: Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
Study: NCT02157506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03558191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: A humanized monoclonal immunoglobulin PD-1 antibody
Study: NCT00735085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV334
Description: 1000mg SLV334 as a single dose
Study: NCT01390818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409 (PI3K and mTOR inhibitor)
Description: SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
Study: NCT00735085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV334
Description: 1000mg SLV334 b.i.d. for one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV334
Description: 2000mg SLV334 b.i.d. for one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV334
Description: 2000mg SLV334 b.i.d. for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SLV334 Placebo arm
Study: NCT03457103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)
Description: Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Description: Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
Study: NCT04140617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to aerosol of electronic cigarette
Description: Exposure to aerosol of electronic cigarette (30 min)
Study: NCT03457103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Description: Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
Study: NCT03689062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction of labor
Description: oxytocin intravenous drip
Study: NCT02238210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent®
Study: NCT04495270

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale
Description: Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
Study: NCT04312880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IV and topical form of TXA will be administered to patients in the respective groups.
Study: NCT03689062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: follow up
Description: hospitalization and antibiotics
Study: NCT02031822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided Greater Occipital Nerve Injection
Description: Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided Greater Occipital Nerve Injection
Description: Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
Study: NCT02319096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy
Description: Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
Study: NCT02183623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg BI 1356 BS
Study: NCT02527122

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allergen extracts